Product Information
FEXOFENADINE-PSE ER 180-240 TB is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.8669 per EA under NDC 55111055735. Its NADAC has been published 87 times since May 22, 2024.
FDA first approved this application on Jun 22, 2011.
Strength
180; 240 mg/1; mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
55111055735
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
1/22/2025
Active Ingredients
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA079043FDA Approved
6/22/2011
On Market Since
8/24/2011
Pharmacological Classes
Price Statistics
The NADAC for FEXOFENADINE-PSE ER 180-240 TB has been published 87 times since May 22, 2024, and over the history we have for it it has declined 12.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8669 per EA |
|---|---|
| All-time high | $1.0292 (Jul 10, 2024) |
| All-time low | $0.8669 (Nov 20, 2024) |
| 52-week high | $0.8669 |
| 52-week low | $0.8669 |
| Median price | $0.8669 |
| Average price | $0.8936 |
| Largest weekly change | -8.7% (Aug 21, 2024) |
| Weeks tracked | 87 |
| Tracking since | May 22, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
N/A
5Y
N/A
All
-12.1%
Last surveyed Jan 14, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Fexofenadine HCl and Pseudoephedrine HCI market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fexofenadine HCl and Pseudoephedrine HCI market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FEXOFENADINE-PSE ER 180-240 TB?
The current National Average Drug Acquisition Cost (NADAC) for FEXOFENADINE-PSE ER 180-240 TB, manufactured by Dr. Reddy's Laboratories Inc., is $0.8669 per EA (NDC 55111055735), effective Jan 14, 2026.
How has the price of FEXOFENADINE-PSE ER 180-240 TB changed over time?
Over the history we have for it, the NADAC for FEXOFENADINE-PSE ER 180-240 TB has declined 12.1%. It has been tracked across 87 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for FEXOFENADINE-PSE ER 180-240 TB?
Since May 22, 2024, the NADAC for FEXOFENADINE-PSE ER 180-240 TB has ranged from a low of $0.8669 (Nov 20, 2024) to a high of $1.0292 (Jul 10, 2024), with a median of $0.8669 per EA.
Are there cheaper alternatives to FEXOFENADINE-PSE ER 180-240 TB?
No other NADAC-published product currently shares the active ingredient and strength of FEXOFENADINE-PSE ER 180-240 TB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FEXOFENADINE-PSE ER 180-240 TB?
FEXOFENADINE-PSE ER 180-240 TB (NDC 55111055735) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.